Omeros (OMER) Stock Forecast & Price Target

Omeros is attractive fundamentally because its U.S. Yartemlea launch is already showing strong commercial traction, with 2Q sales of $28.5M, 74 unique ordering accounts, and about 75% of orders coming from adults, suggesting broad adoption rather than a narrow early-center effect. The launch also benefits from two near-term reimbursement tailwinds, as the permanent J-code went live July 1 and NTAP begins October 1, which should reduce billing friction and improve inpatient economics while supporting an estimated 35-40% peak U.S. market share and roughly $400M in peak sales. Even with Europe excluded after the negative CHMP opinion in June, the stock still appears to have meaningful upside from the core U.S. opportunity and the NVO partnership, which add incremental value without needing a European turnaround.

Omeros is facing a materially weakened investment case after the CHMP adopted a negative opinion on narsoplimab in TA-TMA, removing the modeled EU opportunity and highlighting how dependent the company is on this asset near term. The rejection stemmed from a pivotal study without a comparator arm and insufficient pediatric data, raising serious questions about evidentiary strength, regulatory path, and whether positive clinical results will translate into approval or commercial uptake. With intense competition, higher go-forward R&D spend, and a risk-adjusted DCF already discounted by a 13.1% WACC and reduced exit multiple, the company’s path to profitability and value creation appears increasingly uncertain.